BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res 2018;7:15-28. [PMID: 29144165 DOI: 10.2217/cer-2017-0068] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev 2021;22:11-4. [PMID: 34377737 DOI: 10.1016/j.omtm.2021.06.012] [Reference Citation Analysis]
2 Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W, Longworth L, Meunier A, Moutié AS, Palmer S, Pemberton-Whiteley Z, Ratcliffe M, Shen J, Sproule D, Zhao K, Shah K. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ 2020;21:1421-37. [PMID: 32794011 DOI: 10.1007/s10198-020-01212-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
3 Aballéa S, Thokagevistk K, Velikanova R, Simoens S, Annemans L, Antonanzas F, Auquier P, François C, Fricke FU, Malone D, Millier A, Persson U, Petrou S, Dabbous O, Postma M, Toumi M. Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy 2020;8:1822666. [PMID: 33144927 DOI: 10.1080/20016689.2020.1822666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy 2019;7:1601484. [PMID: 31105909 DOI: 10.1080/20016689.2019.1601484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
5 Qiu T, Hanna E, Dabbous M, Borislav B, Toumi M. Regenerative medicine regulatory policies: A systematic review and international comparison. Health Policy 2020;124:701-13. [PMID: 32499078 DOI: 10.1016/j.healthpol.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
6 Towse A, Fenwick E. Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment? Value Health 2019;22:677-83. [PMID: 31198185 DOI: 10.1016/j.jval.2019.03.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
7 Benger M, Kinali M, Mazarakis ND. Autism spectrum disorder: prospects for treatment using gene therapy. Mol Autism 2018;9:39. [PMID: 29951185 DOI: 10.1186/s13229-018-0222-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
8 Angelis A, Naci H, Hackshaw A. Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. Pharmacoeconomics 2020;38:1297-308. [PMID: 32960434 DOI: 10.1007/s40273-020-00956-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Shahryari A, Saghaeian Jazi M, Mohammadi S, Razavi Nikoo H, Nazari Z, Hosseini ES, Burtscher I, Mowla SJ, Lickert H. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Front Genet. 2019;10:868. [PMID: 31608113 DOI: 10.3389/fgene.2019.00868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 26.5] [Reference Citation Analysis]
10 Qiu T, Wang Y, Liang S, Han R, Toumi M. Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. Regen Med 2021;16:733-55. [PMID: 34431716 DOI: 10.2217/rme-2021-0011] [Reference Citation Analysis]
11 Schaffer SK, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A. Paying for Cures: Perspectives on Solutions to the "Affordability Issue". Value Health 2018;21:276-9. [PMID: 29566833 DOI: 10.1016/j.jval.2017.12.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
12 Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discov Today 2021;26:1602-19. [PMID: 33781953 DOI: 10.1016/j.drudis.2021.03.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zengel J, Carette JE. Structural and cellular biology of adeno-associated virus attachment and entry. Elsevier; 2020. pp. 39-84. [DOI: 10.1016/bs.aivir.2020.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Gavan SP, Lu CY, Payne K. Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. J Pers Med 2019;9:E28. [PMID: 31117188 DOI: 10.3390/jpm9020028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics 2020;38:1165-85. [PMID: 32734573 DOI: 10.1007/s40273-020-00943-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
16 Chapman RH, Kumar VM, Whittington MD, Pearson SD. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets. Value Health 2021;24:839-45. [PMID: 34119082 DOI: 10.1016/j.jval.2021.02.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 He L, Yang H, Tang J, Liu Z, Chen Y, Lu B, He H, Tang S, Sun Y, Liu F, Ding X, Zhang Y, Hu S, Xia L. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J Biol Eng 2019;13:58. [PMID: 31297149 DOI: 10.1186/s13036-019-0189-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
18 Jönsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JG, Wong O. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ 2019;20:427-38. [PMID: 30229376 DOI: 10.1007/s10198-018-1007-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
19 Hlávka JP, Mattke S, Wilks A. The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Appl Health Econ Health Policy 2020;18:669-77. [PMID: 32090302 DOI: 10.1007/s40258-020-00563-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Front Pharmacol 2020;11:594446. [PMID: 33363468 DOI: 10.3389/fphar.2020.594446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Demirci S, Leonard A, Essawi K, Tisdale JF. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease. Mol Ther Methods Clin Dev 2021;23:276-85. [PMID: 34729375 DOI: 10.1016/j.omtm.2021.09.010] [Reference Citation Analysis]
23 Dormer L. Introducing Volume 7 of the Journal of Comparative Effectiveness Research. J Comp Eff Res 2018;7:1-4. [PMID: 29303364 DOI: 10.2217/cer-2017-0087] [Reference Citation Analysis]
24 Padhy SK, Takkar B, Narayanan R, Venkatesh P, Jalali S. Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date. Appl Clin Genet 2020;13:179-208. [PMID: 33268999 DOI: 10.2147/TACG.S230720] [Reference Citation Analysis]
25 Kerpel-Fronius S, Baroutsou V, Becker S, Carlesi R, Collia L, Franke-Bray B, Kleist P, Kurihara C, Laranjeira LF, Matsuyama K, Naseem S, Schenk J, Silva H. Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society. Front Med (Lausanne) 2020;7:608249. [PMID: 33425952 DOI: 10.3389/fmed.2020.608249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Qiu T, Wang Y, Dabbous M, Hanna E, Han R, Liang S, Toumi M. Current state of developing advanced therapies for rare diseases in the European Union. Expert Opinion on Orphan Drugs 2020;8:417-29. [DOI: 10.1080/21678707.2020.1835640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Digiacomo L, Palchetti S, Pozzi D, Amici A, Caracciolo G, Marchini C. Cationic lipid/DNA complexes manufactured by microfluidics and bulk self-assembly exhibit different transfection behavior. Biochem Biophys Res Commun 2018;503:508-12. [PMID: 29733845 DOI: 10.1016/j.bbrc.2018.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
28 van Overbeeke E, Hauber B, Michelsen S, Peerlinck K, Lambert C, Hermans C, Lê PQ, Goldman M, Simoens S, Huys I. Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. Haemophilia 2021;27:957-66. [PMID: 34472162 DOI: 10.1111/hae.14401] [Reference Citation Analysis]
29 Vella Bonanno P, Bucsics A, Simoens S, Martin AP, Oortwijn W, Gulbinovič J, Rothe C, Timoney A, Ferrario A, Gad M, Salem A, Hoxha I, Sauermann R, Kamusheva M, Dimitrova M, Petrova G, Laius O, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Jakupi A, Bochenek T, Wladysiuk M, Furtado C, Marković-Peković V, Mardare I, Meshkov D, Fürst J, Tomek D, Cortadellas MO, Zara C, Haycox A, Campbell S, Godman B. Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. Expert Rev Pharmacoecon Outcomes Res 2019;19:251-61. [PMID: 30696372 DOI: 10.1080/14737167.2019.1575730] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
30 Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, Barrett D. Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments. Mol Ther 2018;26:2717-26. [PMID: 30414722 DOI: 10.1016/j.ymthe.2018.10.017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
31 Shemie G, Nguyen MT, Wallenburg J, Ratjen F, Knoppers BM. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. J Pers Med 2021;11:382. [PMID: 34067090 DOI: 10.3390/jpm11050382] [Reference Citation Analysis]
32 Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? J Comp Eff Res 2021. [PMID: 33663230 DOI: 10.2217/cer-2020-0190] [Reference Citation Analysis]
33 Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol 2021;87:2428-43. [PMID: 32154598 DOI: 10.1111/bcp.14275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
34 Dormer L. Introducing Volume 8 of the Journal of Comparative Effectiveness Research. J Comp Eff Res 2019;8:1-5. [PMID: 30525960 DOI: 10.2217/cer-2018-0119] [Reference Citation Analysis]
35 Pearson SD, Ollendorf DA, Chapman RH. New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options? Value in Health 2019;22:656-60. [DOI: 10.1016/j.jval.2019.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
36 Esrick EB, Bauer DE. Genetic therapies for sickle cell disease. Semin Hematol 2018;55:76-86. [PMID: 29958563 DOI: 10.1053/j.seminhematol.2018.04.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
37 Dormer L. Introducing Volume 9 of the Journal of Comparative Effectiveness Research. J Comp Eff Res 2020;9:1-5. [PMID: 31852215 DOI: 10.2217/cer-2019-0160] [Reference Citation Analysis]
38 Towse A, Mauskopf JA. Affordability of New Technologies: The Next Frontier. Value in Health 2018;21:249-51. [DOI: 10.1016/j.jval.2018.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]